Could Genetic Testing Help Abu Dhabi Prevent Alzheimer's Before Symptoms Appear?

A new clinical trial investigating whether genetic testing could help identify individuals at risk of developing Alzheimer's before symptoms emerge has been launched in Abu Dhabi. This study is being led by the healthcare company M42 and explores the potential for using genetic information to support earlier intervention, with the longer-term aim of preventing or delaying the onset of the disease.

Alzheimer's is a progressive neurological condition that gradually impairs memory, thinking and behaviour. Although its causes are not fully understood, researchers have identified genetic variants associated with an increased risk of developing the disease. One example is the APOE4 allele, a variant of the APOE gene involved in cholesterol transport and metabolism. Carrying this variant increases an individual's likelihood of developing Alzheimer's, although many carriers never develop the condition. Genetic testing can therefore provide an indication of risk, rather than a definite prediction.

Genetic information from more than 900,000 Emiratis collected by the Emirati Genome Programme will be drawn upon in the trial to help identify individuals who may be eligible to participate. M42’s research organisation, IROS, is collaborating with the Department of Health - Abu Dhabi and biotechnology company Halia Therapeutics to investigate how genetic information could support new approaches to Alzheimer’s prevention.

Additionally, the trial will investigate the experimental drug HT-4253, developed by Halia Therapeutics, to assess its potential in preventing Alzheimer’s among individuals who carry the APOE4 variant but have not developed symptoms.

According to research, biological changes associated with Alzheimer's may begin several years before any noticeable memory loss occurs. Identifying individuals who are at a greater risk may create opportunities for earlier intervention before symptoms develop. However, an important distinction remains between estimating someone's risk of developing the disease and being able to prevent it. Whether genetic risk assessment can lead to better clinical outcomes is still being investigated. Importantly, genetic testing alone cannot establish whether the biological changes associated with Alzheimer's have already begun, since identifying an increased genetic risk is different from detecting these changes.

Questions about the value of implementing genetic screening on a larger scale also arise, especially when proven preventative treatments remain limited.

Such programmes would necessitate significant investment in sequencing technology, specialist staff and secure data systems. In addition to this, ethical concerns persist. These concerns include the psychological effects of genetic testing on individuals identified as having a higher risk of Alzheimer’s. For example, an individual may experience severe anxiety over a condition they may never develop, particularly when there are limited options available to minimise that risk.

With all this considered, the ability to identify higher-risk individuals would still be valuable for medical research. It could enable researchers to recruit more suitable participants for clinical trials and investigate potential treatments before symptoms develop. The long-term burden of Alzheimer's on patients, families and healthcare services could also be reduced if earlier identification and effective preventative therapies become available.

When it comes to deciding whether to invest in widespread genetic screening, healthcare providers must weigh these possible benefits against the costs and uncertainties. Resources remain limited and funding for preventative technologies must be considered in parallel with other healthcare priorities. The clinical value of screening will ultimately depend on whether identifying genetic risk leads to meaningful improvements in patient outcomes.

Abu Dhabi's trial reflects a growing interest in using genomic research to move healthcare towards earlier detection and prevention. Although its long-term impact remains uncertain, the study highlights an important question for the future of personalised medicine: how can advances in genetic research be translated into treatments that are not only scientifically effective, but also practical and accessible to patients?